Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INI-2004 in healthy volunteers and allergic rhinitis
NCT06038279Phase 1Completed
- Sponsor
- Inimmune Corporation
- Start
- Jul 2023
- Primary completion
- Sep 2024
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INI-2004 in allergic rhinitis (AR) (9 arms), sponsored by Inimmune Corporation. Primary endpoints: Treatment-Emergent Adverse Events at 58 days, Serious Adverse Events at 58 days and 10 more. Started Jul 2023; status: completed.
02
Drugs
INI-2004
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06038279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06038279.